Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 7, showing 10 Applications out of 69 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

21.

ECCT/23/11/04   AUB Study
    A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.   
Principal Investigator(s)
1. Dr Alice Kaaria
Site(s) in Kenya
Kenyatta National Hospital (KNH)
 
15-04-2024 View

22.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
11-01-2024 View

23.

ECCT/23/10/02   MATRIX-001 protocol
    A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir       
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
11-01-2024 View

24.

ECCT/23/09/05   LCCC 2236 Study
    LCCC  2236: Phase I study of self-administered Artesunate pessaries (vaginal inserts) for treatment of cervical precancer in HIV positive and HIV-negative women in Kenya    
Principal Investigator(s)
1. Chemtai Mungo
2. Jackton Omoto
Site(s) in Kenya
FACES, Lumumba Sub-county Hospital
 
11-01-2024 View

25.

ECCT/23/09/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Doreen Terry Karimi
Site(s) in Kenya
Gertrudes Childrens Hospital
 
07-12-2023 View

26.

ECCT/23/04/02   Shigella 53G study in Kenya
    Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study   
Principal Investigator(s)
1. Melissa Kapulu
2. Fredrick Sawe
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
21-08-2024 View

27.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
19-06-2023 View

28.

ECCT/22/09/03   SINGLE DOSE VERSUS EXTENDED DO
    EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI    OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL.   
Principal Investigator(s)
1. STEVEN ODHIAMBO JUMA
Site(s) in Kenya
JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL
 
26-09-2022 View

29.

ECCT/22/08/04   Protocol H06_01TP
    A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2)           
Principal Investigator(s)
1. Deborah Chepngeno Langat Langat
Site(s) in Kenya
KEMRI WRP CRC KERICHO
 
23-11-2022 View

30.

ECCT/22/04/02   GO42144
    A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS        
Principal Investigator(s)
1. Mansoor Noorali Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
19-08-2022 View